JPMorgan Chase & Co. Issues Positive Forecast for Grifols (NASDAQ:GRFS) Stock Price

Grifols (NASDAQ:GRFS) had its target price increased by JPMorgan Chase & Co. from $7.60 to $10.30 in a report issued on Tuesday morning,Benzinga reports. JPMorgan Chase & Co. currently has a neutral rating on the biotechnology company’s stock.

Separately, Wall Street Zen raised Grifols from a “hold” rating to a “buy” rating in a report on Friday, May 23rd.

Grifols Stock Down 2.4%

Shares of GRFS stock opened at $8.87 on Tuesday. The company has a debt-to-equity ratio of 1.13, a quick ratio of 0.97 and a current ratio of 2.60. The firm’s 50-day moving average is $7.78 and its 200-day moving average is $7.58. The stock has a market cap of $6.10 billion, a price-to-earnings ratio of 7.58, a PEG ratio of 0.32 and a beta of 0.53. Grifols has a 52-week low of $5.79 and a 52-week high of $9.96.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of GRFS. Versant Capital Management Inc bought a new stake in shares of Grifols during the first quarter worth approximately $28,000. Tower Research Capital LLC TRC lifted its holdings in Grifols by 354.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,124 shares of the biotechnology company’s stock worth $60,000 after purchasing an additional 6,335 shares during the last quarter. Blue Trust Inc. boosted its stake in Grifols by 344.4% in the 4th quarter. Blue Trust Inc. now owns 8,697 shares of the biotechnology company’s stock valued at $65,000 after purchasing an additional 6,740 shares during the period. First Trust Advisors LP bought a new stake in Grifols in the 4th quarter valued at $75,000. Finally, Envestnet Portfolio Solutions Inc. acquired a new position in Grifols in the 4th quarter valued at $77,000.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.